0000000000606723

AUTHOR

Mary Clare Luca

showing 5 related works from this author

Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial fu…

2010

Endothelium-dependent flow-mediated dilation (FMD) is measured as the increase in diameter of a conduit artery in response to reactive hyperemia, assessed either at a fixed time point [usually 60-s post-cuff deflation (FMD60)] or as the maximal dilation during a 5-min continuous, ECG-gated, measurement (FMDmax-cont). Preliminary evidence suggests that the time between reactive hyperemia and peak dilation (time to FMDmax) may provide an additional index of endothelial health. We measured FMDmax-cont, FMD60, and time to FMDmax in 30 young healthy volunteers, 22 healthy middle-aged adults, 16 smokers, 23 patients with hypertension, 40 patients with coronary artery disease, and 22 patients wit…

AdultMaleAdolescentBrachial ArteryEndotheliumPhysiologyCoronary Artery DiseaseElectrical conduitForearmPhysiology (medical)medicineHumanscardiovascular diseasesEnzyme InhibitorsReactive hyperemiaHeart FailureAnalysis of Variancebusiness.industrySmokingMiddle AgedVasodilationNG-Nitroarginine Methyl Estermedicine.anatomical_structureRegional Blood FlowAnesthesiaHypertensionCirculatory systemcardiovascular systemDilation (morphology)FemaleEndothelium VascularCardiology and Cardiovascular MedicinebusinessBlood vesselArteryAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study

2011

Studies have demonstrated that the acute administration of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has protective effects in the setting of ischemia-reperfusion (IR). Previously, we demonstrated that a single dose of rosuvastatin prevented IR-induced endothelial dysfunction in humans through a cyclooxygenase-2-dependent mechanism. Whether the chronic administration of HMG-CoA reductase inhibitors provides similar protection remains controversial and is unknown in humans. Eighteen male volunteers were randomized to receive a single dose of rosuvastatin (20 mg) or placebo. Twenty-four hours later, endothelium-dependent, radial artery flow-mediated dilation (FMD) w…

AdultMaleTime FactorsAdolescentEndotheliumPhysiologyCoenzyme AHyperemiaPharmacologyReductaseDrug Administration ScheduleYoung Adultchemistry.chemical_compoundDouble-Blind MethodIschemiaIn vivoPhysiology (medical)medicineHumansRosuvastatinRosuvastatin CalciumOntarioAnalysis of VarianceSulfonamidesCyclooxygenase 2 Inhibitorsbiologybusiness.industryFluorobenzenesVasodilationRosuvastatin CalciumPyrimidinesmedicine.anatomical_structurechemistryCelecoxibRegional Blood FlowReperfusion InjuryRadial ArteryHMG-CoA reductasebiology.proteinCelecoxibPyrazolesHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans.

2010

Objectives We aimed to assess whether concurrent administration of atorvastatin would modify the development of tolerance and endothelial dysfunction associated with sustained nitroglycerin (GTN) therapy in humans. Background Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors can protect against GTN-induced endothelial dysfunction and tolerance, likely through an antioxidant mechanism. Methods Thirty-six healthy male volunteers were randomized to receive continuous transdermal GTN (0.6 mg/h) and placebo, atorvastatin (80 mg/day) alone, or continuous transdermal GTN (0.6 mg/h) with concurrent atorvastatin (80 mg/day), all for 7 …

AdultMalemedicine.medical_specialtyEndotheliumendotheliumAdolescentBrachial Arterymedicine.medical_treatmentAtorvastatinVasodilator AgentsBlood PressurePlaceboNitroglycerinYoung AdultDouble-Blind MethodHeart RateReference ValuesInternal medicinemedicineAtorvastatinHumansPyrrolesEndothelial dysfunctionSalinetolerancebiologybusiness.industryDrug Administration RoutesDrug Tolerancemedicine.diseaseVasodilationOxidative StressBlood pressuremedicine.anatomical_structureEndocrinologyHeptanoic AcidsCirculatory systemHMG-CoA reductasebiology.proteincardiovascular systemlipids (amino acids peptides and proteins)Endothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drugcirculatory and respiratory physiologyJournal of the American College of Cardiology
researchProduct

Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study

2009

Damage and dysfunction of the vascular endothelium critically influence clinical outcomes after ischemia and reperfusion (I/R). Brief exposure to organic nitrates can protect the vascular endothelium from I/R injury via a mechanism that is similar to ischemic preconditioning and is independent of hemodynamic changes. The clinical relevance of these protective effects clearly depends on whether they can be sustained over time. Twenty-four healthy (age 25–32) male volunteers were randomized to receive 1) transdermal nitroglycerin (GTN; 0.6 mg/h) administered for 2 h on 1 day only, 2) transdermal GTN for 2 h/day for 7 days, or 3) continuous therapy with transdermal GTN for 7 days. Eight volunt…

AdultMalemedicine.medical_specialtyEndotheliumPhysiologyVasodilator AgentsIschemiaAscorbic AcidAdministration CutaneousAntioxidantsNitroglycerinIn vivoPhysiology (medical)Internal medicinemedicineHumansInfusions Intra-ArterialIschemic PreconditioningNitroglycerinDose-Response Relationship Drugbusiness.industryDrug Tolerancemedicine.diseaseAcetylcholineOrganic nitratesPlethysmographyVascular endotheliummedicine.anatomical_structureReperfusion InjuryAnesthesiaCirculatory systemcardiovascular systemCardiologyIschemic preconditioningEndothelium VascularCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2–Dependent Mechanism

2010

ObjectivesThe purpose of this study was to determine whether single-dose rosuvastatin (40 mg) protects against ischemia and reperfusion (IR)–induced endothelial dysfunction in humans and whether this effect is cyclooxygenase (COX)-2 dependent.BackgroundAnimal studies have demonstrated that rosuvastatin can limit damage and improve recovery after IR.MethodsIn a double-blind, parallel design, 20 volunteers were randomized to a single dose of oral rosuvastatin (40 mg) or placebo. Twenty-four hours later, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery was measured before and after IR (15 min of upper arm ischemia followed by 15 min of reperfusion). In a separate protoc…

AdultMaleEndotheliumendotheliumAdolescentPremedicationIschemiaMyocardial Reperfusion InjuryPharmacologyPlaceboYoung AdultDouble-Blind Methodmedicineischemia reperfusionHumansRosuvastatinEndothelial dysfunctionRosuvastatin CalciumSulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryModels Cardiovascularnutritional and metabolic diseases3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitormedicine.diseaseFluorobenzenesVasodilationRosuvastatin Calciummedicine.anatomical_structurePyrimidinesCelecoxibCyclooxygenase 2AnesthesiaIschemic Preconditioning MyocardialRadial ArteryCelecoxibIschemic preconditioningPyrazolesFemaleEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular Medicinerosuvastatinmedicine.drugJournal of the American College of Cardiology
researchProduct